Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PRGN-3006||PRGN-3006 is a cell-based therapy comprising autologous T-cells engineered to express membrane-bound IL15 and a chimeric antigen receptor (CAR) that recognizes CD33 as well as a kill switch, potentially resulting in increased anti-tumor response against CD33-expressing tumor cells (Blood (2019) 134 (Supplement_1): 2660).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03927261||Phase I||PRGN-3006||PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS||Recruiting|